3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
6
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Gastrointestinal Neoplasms
1
GastroEsophageal Cancer
1
Gastric or Gastroesophageal Cancer
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
35
Nivolumab
13
Cyclophosphamide
11
fludarabine
9
aldesleukin
9
atezolizumab
7
Magnetic Resonance Spectroscopy
7
Carboplatin
7
Specimen Handling
6
Ipilimumab
6
Early Intervention, Educational
6
Cisplatin
6
Trastuzumab
5
Paclitaxel
5
Methods
5
Biopsy
5
Bevacizumab
5
durvalumab
4
Vaccines
4
Surveys and Questionnaires
4
Radiotherapy
4
Papillomavirus Vaccines
4
Interleukin-2
4
Docetaxel
4
tisotumab vedotin
3
spartalizumab
3
fludarabine phosphate
3
cemiplimab
3
aflibercept
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
bemarituzumab
×
Gastrointestinal
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled